DALLAS, Sept. 22, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring immunotherapy drug for cancer and infectious disease developer CEL-SCI Corp. (AMEX:CVM). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on CEL-SCI Corp. (AMEX:CVM) should be of particular interest to other oncology and/or infectious disease-oriented therapeutics companies: Celldex Therapeutics Inc. (Nasdaq:CLDX), ZymoGenetics Inc. (Nasdaq:ZGEN)), Idera Pharmaceuticals Inc. (Nasdaq:IDRA) and Alexion Pharmaceuticals Inc. (Nasdaq:ALXN).

The full report is available at: http://www.stockpreacher.com/n/CVM

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

CEL-SCI Corp. (CVM) engages in the development of immune-based cancer and infectious disease therapies. Its lead product, Multikine, the first of a new class of cancer immunotherapy drugs, simulates the activities of a healthy person's immune system, which battles cancer every day. The drug is cleared by the FDA and Canadian regulators for a global phase III clinical trial in newly diagnosed head and neck cancer.

The Company also develops a heteroconjugate technology referred to as L.E.A.P.S. (Ligand Epitope Antigen Presentation System), which is intended to selectively stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own.

Message Board Search for CVM: http://www.boardcentral.com/boards/CVM

In the report, the analyst notes:

"Leveraging the LEAPS technology, CVM recently created a potential peptide vaccine/treatment against H1N1 swine flu, positioning itself as a player in the competitive H1N1 arena. On September 16, CVM moved forward when it was advised by the U.S. Food and Drug Administration that it could proceed with its first clinical trial to evaluate the effect of LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

"Looking to commence a pivotal phase III clinical trial with its cancer drug Multikine, and to rapidly take its much touted new LEAPS - H1N1 compound into human studies, CSM recently entered into definitive agreements to sell 14.3 million shares of its common stock at a price per share of $1.40 pursuant to a registered direct offering to institutional investors, representing gross proceeds of approximately $19 million."

To read the entire report visit: http://www.stockpreacher.com/n/CVM

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT: StockPreacher.com
         Jeff Bishop
         (469)-252-3505
         press@beaconequity.com